Anoikis resistance and metastasis of ovarian cancer can be overcome by CDK8/19 mediator kinase inhibition
Anoikis resistance, or evasion of cell death triggered by matrix detachment, is a hallmark of cancer cell survival and metastasis. We showed that repeated exposure to suspension stress followed by recovery under attached conditions leads to development of anoikis resistance. The acquisition of anoikis resistance was associated with enhanced invasion, chemoresistance, and immune evasion in vitro and distant metastasis in vivo. This acquired anoikis resistance was not genetic, persisting for a finite duration without detachment stress, but was sensitive to CDK8/19 mediator kinase inhibition that could also reverse anoikis resistance. Transcriptomic analysis revealed that CDK8/19 kinase inhibition induces bidirectional transcriptional changes in both sensitive and resistant cells, disrupting the balanced reprogramming required for anoikis adaptation and resistance by reversing some resistance-associated pathways and enhancing others. Both anoikis resistance and in vivo metastatic growth of ovarian cancers are sensitive to CDK8/19 inhibition, thereby providing a therapeutic opportunity to both prevent and suppress ovarian cancer metastasis.
Authors
- Igor B. Roninson (ORCID: https://orcid.org/0000-0002-9211-1327)
- Nadine Hempel
- Mehri Monavarian (ORCID: https://orcid.org/0000-0002-3320-2974)
- Asha Kumari (ORCID: https://orcid.org/0000-0002-2508-9879)
- Ianov Lara
- Karthikeyan Mythreye
- Resha Rajkarnikar
- Emily Faith Page
- Liz Quintero Macias
- Felipe Massicano
- Mohit Kumar Jolly
- Mengqian Chen
- Sarthak Sahoo
- Elizabeth Worthey
- Abhyudai Singh
- Nam Y. Lee
Institutions
- University of Arizona (US)
- University of South Carolina (US)
- University of Alabama at Birmingham (US)
- University of Pittsburgh Medical Center (US)
- Indian Institute of Science Bangalore (IN)
- University of Delaware (US)
Publication Details
- Journal
- JCI Insight
- Published
- 2026-01-15
- DOI
- https://doi.org/10.1172/jci.insight.192113
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- University of South Carolina
- National Institutes of Health
- University of Texas MD Anderson Cancer Center